<DOC>
	<DOCNO>NCT00382148</DOCNO>
	<brief_summary>This Phase IIb , multicenter , open-label study available active ( Xolair ) control ( placebo ) subject complete final visit ( early termination visit , applicable ) Study Q2788g , meet eligibility criterion study , provide consent participate study .</brief_summary>
	<brief_title>A Study Xolair Peanut-Allergic Subjects Previously Enrolled Study Q2788g</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Completion last visit ( early termination visit , applicable ) Study Q2788g Signed Informed Consent Form Use effective method contraception female childbearing potential Body weight ≥ 20 kg ≤ 150 kg IgE level ≤ 1300 IU/mL ( Note : Subjects IgE &lt; 30 IU/mL dose low level dose table [ 30 IU/mL ] , thus enable well understanding role Xolair peanut allergic subject low total IgE level . ) Withdrawal Study Q2788g prior study closure final study visit ( Week 36 ) Current participation another investigational study Pregnancy lactation History brittle asthma Aspirinsensitive asthma Known hypersensitivity ingredient Xolair , include excipients ( sucrose , histidine , polysorbate 20 ) Have polymorrphonuclear count &lt; 1500/uL Use anticoagulant , warfarin ( Coumadin ( R ) ) , thrombolytic enzyme , ticlopidine Current diagnosis cancer , current investigation possible cancer , history cancer ( include nonmelanoma skin cancer ) Thrombocytopenia evidence platelet count &lt; 100,000/uL Any systemic condition require regular administration immunoglobulin</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>TOPS</keyword>
	<keyword>Peanut allergy</keyword>
	<keyword>Peanut-induced allergy</keyword>
	<keyword>Allergy</keyword>
</DOC>